

VERTEX PHYSICIANS IN PHARMACEUTICALS PROGRAMME

*A world-class, 12-month Programme
at our International Headquarters in
Paddington, London.*



PROGRAMME OVERVIEW



The Vertex Physicians in Pharmaceuticals Programme (VPiPP) is a unique, one-year work placement for exceptional physicians in training who wish to enrich their curriculum and knowledge by understanding and experiencing pharmaceutical medicine.

Our Physicians are integrated into the Vertex Medical Affairs team, contributing to the development of activities in one or more of Vertex's therapeutic areas.

You also have the opportunity to understand other areas of Pharmaceutical Medicine, such as clinical development, patient safety, and regulatory affairs, through rotations and/or shadowing opportunities.

PROGRAMME OBJECTIVES

- Help patients by contributing to the development of transformative medicines
- Learn about pharmaceutical medicine to enrich your career
- Contribute towards the development of our therapeutic areas in a team-based environment
- Receive exposure to scientific, medical, and business leaders
- Competitive compensation package

REQUIRED EXPERIENCE

- An MDs/MBBS, or MD/MBBS
- Completed your specialty training, be enrolled in a recognised specialty training programme and 1-2 years before completion (UK - CCT) or be utilising your Out Of Programme (OOPC) year
- Expertise and background in one of the following specialties is an advantage: Nephrology, Haematology, Endocrinology/Diabetology, Neurology and Pain Management
- Evidence of academic distinction and/or research work

COMPANY OVERVIEW

QUICK FACTS

- Founded in 1989
- Reshma Kewalramani, MD, CEO and President
- Headquarters in Boston, MA and London, UK
- ~ 5500 employees worldwide
- >70% of operating expenses dedicated to RD

OUR VALUES

It's not just about what we do, but how we do it. Our values are our bedrock, and together with our culture, they enable us to achieve our mission: creating transformative medicines for serious diseases.



OUR AWARDS



Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people living with serious diseases.

We are serial innovators, committed to developing medicines that treat the underlying cause of disease, not just the symptoms. We have multiple medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease, and we continue to serially innovate in sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), advancing clinical and research programmes in these diseases. We also have a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where we have deep insight into causal human biology. At the end of 2023, this included acute and neuropathic pain, APOL1-mediated kidney disease (AMKD), type 1 diabetes (T1D), myotonic dystrophy type 1 (DM1) and alpha-1 antitrypsin deficiency (AATD). Our preclinical pipeline, which represents the next wave of innovation, is also broad, diverse and rapidly advancing.

Vertex is consistently recognised as one of the industry's top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards.

Take your first step into an impactful career with Vertex.

For more information, contact:
Brendan Bacon, brendan_bacon@vrtx.com

To browse all open positions, visit:
https://vrtx.wd501.myworkdayjobs.com/Vertex_Careers